Advances in the progress of monoclonal antibodies for rabies. Issue 1 (31st January 2022)

• Record Type: Journal Article
• Authors: Fan, Linlin; Zhang, Li; Li, Jingxin; Zhu, Fengcai
• Is Part Of: Human vaccines & immunotherapeutics. Volume 18:Issue 1(2022)
• Publication Date: 2022-01-31
• Subjects: Rabies virus -- glycoprotein -- monoclonal antibody -- antibody library -- antibody cocktail; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2022.2026713
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Rabies is a highly fatal zoonotic disease caused by the rabies virus invading the central nervous system. When suspected of exposure to the rabies virus, post-exposure prophylaxis should be administered as soon as possible. Monoclonal antibodies (mAbs) neutralizing the rabies virus could be better in human rabies post-exposure prophylaxis than equine or human rabies immune globulin in terms of supply, cost, and efficacy. This article reviews anti-rabies mAbs produced by multiple techniques, and the results of clinical trials for anti-rabies mAbs cocktails recognizing non-overlapping epitopes are also discussed.